GILUPI is a Potsdam-based medical device company that has developed the “Nanodetector Cancer 01” to specifically isolate tumor cells from a patient’s circulating blood via antibodies bound on the nanodetector. The isolated cells are intended for analysis of genetic status and detection of genetic aberrations. The company plans to use the newly raised funds mainly to pursue CE certification and subsequent market introduction of its patented detector. That approval was expected in 2011 according to the article. GILUPI was founded in 2006 by CEO Klaus Lücke and operates out of the Science Park of Potsdam-Golm. The company recently completed its third round of funding totaling €3.6M.

Total raised

$5M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2011